Clinical trials: Visceral Leishmaniosis
Leishmaniasis, Visceral
Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)
According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.
- Trial name
- NCT06793111
- Where
- 5 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Visceral Leishmaniasis, Kala Azar
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
A cluster-randomized vector control trial in Bihar, India, and neighboring Nepal, will test the efficacy of long-lasting impregnated bednets (LLINs, Permanets) for reducing visceral leishmaniasis incidence.
- Trial name
- KALANET (NCT00318721)
- Testing
- Long Lasting Impregnated Nets (LLIN)
- Where
- 2 sites in India, Nepal
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Invasive Fungal Infections, Neutropenic Fever
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
A single-center, randomized, open-label, single-dose, two-period, double-crossover study to evaluate the bioequivalence of liposomal amphotericin B for injection (test product) manufactured by Sichuan Huiyu Pharmaceutical Co.…
- Conditions
- Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
- Trial name
- NCT06983665
- Testing
- Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.), Reference product (AmBisome®, Astellas Pharma US Inc.)
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
Visceral leishmaniasis (VL) is a fatal disease caused by Leishmania parasites and transmitted by female phlebotomine sandflies. The disease is a serious public health problem in eastern Africa; including Kenya where an estimated…
- Trial name
- rK28-AccDemo (NCT05386875)
- Testing
- rK28
- Where
- 4 sites in Kenya
- Volunteers
- 625 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Visceral Leishmaniasis
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of Astellas Pharma US, Inc., in patients…
- Trial name
- NCT03636659
- Testing
- Amphotericin B Liposome, AmBisome (Amphotericin B) Liposome
- Where
- 3 sites in Bangladesh, India
- Volunteers
- 140 people
- Sponsor
- Aurobindo Pharma Ltd
Visceral Leishmaniasis
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.
- Trial name
- NCT00255567
- Testing
- Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate
- Where
- 5 sites in Ethiopia, Kenya and 2 more
- Volunteers
- 1,142 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis, Immune Response
Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine
This study is designed to evaluate the immune and therapeutic responses of visceral leishmaniasis patients using N-acetylcysteine (NAC) as an adjuvant therapy to pentavalent antimony.
- Conditions
- Visceral Leishmaniasis, Immune Response, Treatment
- Trial name
- VLNAC (NCT01138956)
- Testing
- N-acetylcysteine, Pentavalent antimonial
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Leishmaniasis
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
L. infantum leishmaniasis is endemic in the South of France. For several years, there has been an expansion of the territory of sandflies (vector of leishmaniasis), with the appearance of cases of canine leishmaniasis in new…
- Trial name
- AsymptoGen (NCT03784248)
- Testing
- blood donation and isolation of leuco-platelet layers
- Where
- France
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Visceral Leishmaniasis, Human African Trypanosomiasis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Tropical fevers have been a diagnostic challenge from the antiquity. Nowadays, despite the availability of good diagnostic capacities, undifferentiated febrile illnesses continue to be a thorny problem for travel physicians.
- Conditions
- Visceral Leishmaniasis, Human African Trypanosomiasis, Enteric Fever, Melioidosis
- Trial name
- NCT01766830
- Testing
- rk28 ICT, IT LEISH (rK39), Immunochromatographic HAT test
- Where
- 7 sites in Cambodia, Democratic Republic of the Congo and 2 more
- Volunteers
- 1,927 people
- Sponsor
- University Hospital, Geneva
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Visceral Leishmaniasis
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
The purpose of this study is to evaluate the effectiveness of treatment with PMIM in patients with visceral leishmaniasis within the VL-endemic region of Bangladesh at EOT (21/22 days after treatment begins), and at 6 months…
- Trial name
- NCT01328457
- Testing
- Paromomycin sulfate
- Where
- 3 sites in Bangladesh
- Volunteers
- 120 people
- Sponsor
- PATH
Visceral Leishmaniasis, Cutaneous Leishmaniases
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose.
- Trial name
- NCT03929016
- Testing
- DNDI-0690
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Leishmaniasis, Cutaneous
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases.
- Trial name
- Asymptoleish (NCT03303898)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Leishmaniasis, Visceral
Predicting Visceral Leishmaniasis in HIV Infected Patients
In this cohort study, the investigators will study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV-infected individuals from VL endemic regions in Ethiopia as an avenue to develop an…
- Trial name
- PreLeisH (NCT03013673)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 566 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
Improved Case Detection and Vector Control for Visceral Leishmaniasis
Visceral leishmaniasis (VL) also known as kala-azar is a public health problem in Bangladesh. Since 2005 a national kala-azar elimination program is going on in the country.
- Trial name
- NCT03269006
- Testing
- Inesfly Paint, IDWL (1m), ITN (KO-Tab 123)
- Where
- Bangladesh
- Volunteers
- 202 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis
Amphotericin B Treatment in Visceral Leishmaniasis
This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses.
- Trial name
- NCT00310505
- Testing
- Amphotericin B deoxycholate given as daily administration
- Where
- India
- Volunteers
- 1,500 people
- Sponsor
- Banaras Hindu University
Leishmaniasis, Visceral
Combination Therapy in Indian Visceral Leishmaniasis
Rationale The overall objective of this trial is to identify a safe and effective combination, (co-administration) short course treatment for the treatment of VL which could be easily deployed in a control programme.
- Trial name
- NCT00523965
- Testing
- amphotericin B deoxycholate, Liposomal Amphotericin B with Miltefosine, Liposomal Amphotericin B and Paromomycin Sulfate
- Where
- India
- Volunteers
- 624 people
- Sponsor
- Banaras Hindu University
Visceral Leishmaniasis
Clinical Prognostic Score to Predict Relapse in VL
This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia.
- Trial name
- CPS (NCT05602610)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 741 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Hiv, Visceral Leishmaniasis
Recurrent Visceral Leishmaniasis in HIV Co-Infection
The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target…
- Trial name
- ALIVE (NCT07487350)
- Where
- Ethiopia
- Volunteers
- 20 people
- Sponsor
- Institute of Tropical Medicine, Belgium